ATE216889T1 - Anwendung von prostagrandin-analogen für die behandlung von glaukome und okuläre hypertension - Google Patents

Anwendung von prostagrandin-analogen für die behandlung von glaukome und okuläre hypertension

Info

Publication number
ATE216889T1
ATE216889T1 AT94119571T AT94119571T ATE216889T1 AT E216889 T1 ATE216889 T1 AT E216889T1 AT 94119571 T AT94119571 T AT 94119571T AT 94119571 T AT94119571 T AT 94119571T AT E216889 T1 ATE216889 T1 AT E216889T1
Authority
AT
Austria
Prior art keywords
glaucoma
treatment
prostagrandin
analogue
hypertension
Prior art date
Application number
AT94119571T
Other languages
English (en)
Inventor
Verney L Sallee
Louis Desantis Jr
Paul W Zinke
John E Bishop
Peter G Klimko
Robert D Selliah
Thomas R Dean
Mark R Hellberg
Original Assignee
Alcon Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/167,470 external-priority patent/US5721273A/en
Application filed by Alcon Lab Inc filed Critical Alcon Lab Inc
Application granted granted Critical
Publication of ATE216889T1 publication Critical patent/ATE216889T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
    • C07C405/0016—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing only hydroxy, etherified or esterified hydroxy groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT94119571T 1993-12-15 1994-12-10 Anwendung von prostagrandin-analogen für die behandlung von glaukome und okuläre hypertension ATE216889T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16774793A 1993-12-15 1993-12-15
US08/167,470 US5721273A (en) 1993-12-15 1993-12-15 Use of certain 9-halo-13,14-dihydroprostaglandins to treat glaucoma and ocular hypertension
US31667294A 1994-09-30 1994-09-30

Publications (1)

Publication Number Publication Date
ATE216889T1 true ATE216889T1 (de) 2002-05-15

Family

ID=27389393

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94119571T ATE216889T1 (de) 1993-12-15 1994-12-10 Anwendung von prostagrandin-analogen für die behandlung von glaukome und okuläre hypertension

Country Status (4)

Country Link
EP (2) EP0667160B1 (de)
AT (1) ATE216889T1 (de)
AU (1) AU687906B2 (de)
DE (1) DE69430521D1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5631287A (en) * 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
US6011062A (en) * 1994-12-22 2000-01-04 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
WO1998021180A1 (en) * 1995-06-07 1998-05-22 Alcon Laboratories, Inc. Conformationally rigid aryl- or heteroaryl prostaglandins for use in glaucoma therapy
US5814660A (en) * 1995-12-22 1998-09-29 Alcon Laboratories, Inc. 9-oxa prostaglandin analogs as ocular hypotensives
US5866602A (en) * 1995-12-22 1999-02-02 Alcon Laboratories, Inc. Keto-substituted tetrahydrofuran analogs of prostaglandins as ocular hypotensives
DE69633136T2 (de) * 1995-12-22 2005-09-01 Alcon Laboratories, Inc., Fort Worth Substituierte tetrahydrofuran-analoge von prostaglandinen als augendrucksenkende mittel
EP0948333A1 (de) * 1996-11-01 1999-10-13 Alcon Laboratories, Inc. Verwendung einer kombination aus kohlensäure anhydrase inhibitoren und prostaglandinen zur behandlung von glaukom
US6353000B1 (en) * 1996-11-12 2002-03-05 Alcon Laboratories, Inc. 11-halo prostaglandins for the treatment of glaucoma or ocular hypertension
US6458836B1 (en) 2000-03-16 2002-10-01 Sucampo, A.G. Treatment of ocular hypertension and glaucoma
AU2001241143B2 (en) * 2000-03-16 2005-08-25 Sucampo Ag Composition for use in treatment of ocular hypertension and glaucoma
WO2003018025A1 (en) * 2001-08-23 2003-03-06 Sucampo Ag Method and composition for treatment of ocular hypertension and glaucoma
WO2003082257A2 (en) * 2002-03-28 2003-10-09 Sucampo Ag Method for treating ocular hypertension and glaucoma
KR20180058758A (ko) 2015-09-22 2018-06-01 그레이버그 비젼, 인크. 안구 장애의 치료를 위한 화합물 및 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3504044A1 (de) * 1985-02-04 1986-08-07 Schering AG, Berlin und Bergkamen, 1000 Berlin 9-halogenprostaglandin-clathrate und ihre verwendung als arzneimittel
DE3510978A1 (de) * 1985-03-22 1986-09-25 Schering AG, Berlin und Bergkamen, 1000 Berlin Neue 9-halogenprostaglandine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
IL87116A (en) * 1987-07-17 1993-03-15 Schering Ag 9-halogen-(z)-prostaglandin derivatives and pharmaceutical compositions containing the same
DE4024347A1 (de) * 1990-07-27 1992-01-30 Schering Ag Cyclopentanderivate, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung
DE4036140A1 (de) * 1990-11-09 1992-05-14 Schering Ag 9-halogen-11ss-hydroxy-prostaglandinderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
WO1994005631A1 (de) * 1992-08-31 1994-03-17 Schering Aktiengesellschaft 9-chlor-prostaglandin-ester und -amide und ihre verwendung für die herstellung von arzneimitteln
DE4229053A1 (de) * 1992-08-31 1994-03-03 Schering Ag Verwendung von Estern und Amiden von 9-Chlor-Prostaglandinen für die Herstellung von Arzneimitteln zur Förderung der Hautdurchblutung

Also Published As

Publication number Publication date
AU7913894A (en) 1995-06-22
EP0667160A3 (de) 1995-11-15
EP0667160A2 (de) 1995-08-16
DE69430521D1 (de) 2002-06-06
AU687906B2 (en) 1998-03-05
EP1088816A2 (de) 2001-04-04
EP0667160B1 (de) 2002-05-02

Similar Documents

Publication Publication Date Title
ATE202706T1 (de) Verwendung von 9-deoxyprostaglandinderivaten zur behandlung von glaukom
DE68929563D1 (de) Prostaglandin-Derivate zur Behandlung von Glaukom und ocularer Hypertension
ATE286880T2 (de) Verwendung von fluprostenolisopropylester zur herstellung eines arzneimittels zur behandlung von glaukom und okularer hypertension
BR9813767A (pt) Processo e composição para tratar glaucoma de glc1a
DE69634414D1 (de) Verwendung von substituierten isochinolinsulfonyl-verbindungen zur herstellung eines medikaments für die behandlung von glaukom und okularer ischämie
DE60334134D1 (de) Ungsmethode von erhöhtem augeninnendruck und glaukom
ATE216889T1 (de) Anwendung von prostagrandin-analogen für die behandlung von glaukome und okuläre hypertension
EP1110554A4 (de) Medizinische zusammensetzungen zur behandlung von augenerkrankungen
DE3872701D1 (de) Prostaglandin-derivate zur behandlung von glaucoma oder augenueberdruck.
MX24839A (es) 3-arilcarbonil-1-aminoalquilo-1h-indoles, proceso para su preparacion y composicion farmaceutica quelos contiene.
ATE223200T1 (de) Einen carboanhydrase-hemmer und xanthangummi enthaltendes augenarzneimittel
ATE326972T1 (de) Heilende zusammensetzung für intraokulare hypertension oder glaukom
ATE117208T1 (de) Behandlung von intraokularem druck mit einer ophthalmischen synergistischen kombination.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties